Reviva Pharmaceuticals Holdings, Inc. (RVPH)
NASDAQ: RVPH · Real-Time Price · USD
2.120
-0.200 (-8.62%)
Mar 18, 2026, 10:36 AM EDT - Market open
RVPH Employees
Reviva Pharmaceuticals Holdings had 14 employees as of December 31, 2024. The number of employees decreased by 1 or -6.67% compared to the previous year.
Employees
14
Change (1Y)
-1
Growth (1Y)
-6.67%
Revenue / Employee
n/a
Profits / Employee
-$1,625,479
Market Cap
247.72M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 14 | -1 | -6.67% |
| Dec 31, 2023 | 15 | 5 | 50.00% |
| Dec 31, 2022 | 10 | 5 | 100.00% |
| Dec 31, 2021 | 5 | 0 | - |
| Dec 31, 2020 | 5 | 1 | 25.00% |
| Sep 30, 2020 | 5 | 1 | 25.00% |
| Jun 30, 2020 | 4 | - | - |
| Mar 31, 2020 | 4 | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 179 |
| AC Immune | 172 |
| Cabaletta Bio | 151 |
| Nautilus Biotechnology | 130 |
| Foghorn Therapeutics | 106 |
| Camp4 Therapeutics | 55 |
| Protara Therapeutics | 46 |
| Avalo Therapeutics | 23 |
RVPH News
- 2 months ago - Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum - GlobeNewsWire
- 3 months ago - FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug - Benzinga
- 3 months ago - Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia - GlobeNewsWire
- 4 months ago - Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 months ago - Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025 - GlobeNewsWire
- 5 months ago - Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners - GlobeNewsWire
- 6 months ago - Top 3 Health Care Stocks That May Explode In September - Benzinga
- 6 months ago - Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering - GlobeNewsWire